Jamie Feng

5PUBLICATIONS
85CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 14, 2026
Second- and third-line outcomes after selective RET inhibitor failure in RET fusion-positive metastatic lung cancer: A real-world analysis from the RET-MAP registry.

|Jul 02, 2026
TROP2 immunoreactivity in pulmonary large cell neuroendocrine carcinoma.

|Apr 07, 2026
Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry.

Arianna Marinello, Julia K Rotow, Meghanne Lomibao

|Jan 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.

Sarah Waliany, Alissa J Cooper, Stephen V Liu

|Aug 25, 2023
Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression.

Marie-Hélène Denault, Jamie Feng, Shelley Kuang

Pageof 1

Frequent Collaborators

3 joint publications

Julia K Rotow

3 joint publications

Alexander Drilon

2 joint publications

Daniela Miliziano

2 joint publications

David Planchard